) -- A calendar of important, potentially stock-moving biotech events for March:

March 2-3

RBC Capital Markets Healthcare Conference

March 4

Bristol-Myers Squibb

investor/analyst meeting

(BMY) - Get Report

March 5-7

ASCO Genitourinary Cancers Symposium:



presenting updated data from the phase III study of Provenge

March 8-11

Cowen & Co Healthcare Conference

March 9

FDA advisory panel meets to discuss



pirfenidone for the treatment of idiopathic pulmonary fibrosis. The FDA's briefing documents for this meeting likely available on March 5 or March 8.

March 12

FDA approval decision date for exenatide once weekly for diabetes, developed by

Amylin Pharmaceuticals

( AMLN) and


(ALKS) - Get Report

, co-marketed by

Eli Lilly

(LLY) - Get Report


March 14-16

American College of Cardiology annual meeting

March 19



investor/analyst meeting

March 21

FDA approval decision date for

Somaxon Pharmaceuticals'

( SOMX) Silenor for insomnia.

March 24

FDA approval decision date for

Salix Pharmaceuticals'


Xifaxan for hepatic encephalopathy.

Centers for Medicare and Medicaid Services (CMS) advisory committee meeting to discuss erythropoietin-stimulating agents for treatment of chronic kidney disease.


(AMGN) - Get Report


Johnson & Johnson

(JNJ) - Get Report


March 29

FDA approval decision date for


( CEPH) Nuvigil for treatment of jet lag disorder

Ongoing FDA drug reviews with no approval decision date:


(MNKD) - Get Report

Afrezza (inhaled insulin) for diabetes

Companies with important, pending clinical trials:


Allos Therapeutics


Drug: Folotyn in non-small cell lung cancer.

Allos is conducting this phase II study to demonstrate the feasibility of using Folotyn to treat certain patients with non-small cell lung cancer. Folotyn was recently launched commercially as a treatment for peripheral T-cell lymphoma, a relatively small blood cancer indication. The study in non-small cell lung cancer is important because it could potentially expand Folotyn's devlopment to larger, solid tumor cancer indications.




Drug: TNFerade for pancreatic cancer.

GenVec is conducting a second interim analysis of a pivotal phase III study comparing the effect on overall survival of TNFerade plus the standard of care versus standard of care alone in patients with pancreatic cancer.




Drug: Dimebon for Alzheimer's disease.

The phase III study of Dimebon in patients with mild to moderate Alzheimer's disease is shaping up to be one of the biggest binary events in biotech this year. Current Alzheimer's drugs are only moderately effective, so Dimebon has the potential to be a billion dollar-plus blockbuster if it can duplicate the positive results from an earlier, phase II study.


(PFE) - Get Report

is Medivation's partner on Dimebon.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on



Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.